Female Reproductive System Neuroendocrine Carcinoma

Female Reproductive System Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Novartis Pharmaceuticals
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01266447	Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer	completed	Phase 2	27	National Cancer Institute (NCI)NIH	1	Aug 8, 2019	clinicaltrials
NCT00416455	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	completed	Phase 1 / Phase 2	384	National Cancer Institute (NCI)NIH